Jun Qi

List of Publications by Year in Descending Order

114 papers	12,755 citations	40 h-index	112 g-index
120 ext. papers	15,292 ext. citations	14.6 avg, IF	5.52 L-index

#	Paper	IF	Citations
114	A PRC2-Kdm5b axis sustains tumorigenicity of acute myeloid leukemia.. *Proceedings of the National Academy of Sciences of the United States of America*, **2022**, 119,	11.5	1
113	EP300 selectively controls the enhancer landscape of MYCN-amplified neuroblastoma. *Cancer Discovery*, **2021**,	24.4	5
112	Brd4 participates in epigenetic regulation of the extinction of remote auditory fear memory. *Neurobiology of Learning and Memory*, **2021**, 179, 107383	3.1	2
111	Transcriptional programming drives Ibrutinib-resistance evolution in mantle cell lymphoma. *Cell Reports*, **2021**, 34, 108870	10.6	3
110	Development of Dimethylisoxazole-Attached Imidazo[1,2-]pyridines as Potent and Selective CBP/P300 Inhibitors. *Journal of Medicinal Chemistry*, **2021**, 64, 5787-5801	8.3	6
109	Lysine Demethylase 5A is Required for MYC Driven Transcription in Multiple Myeloma. *Blood Cancer Discovery*, **2021**, 2, 370-387	7	4
108	Bromodomain protein BRD4 directs and sustains CD8 T cell differentiation during infection. *Journal of Experimental Medicine*, **2021**, 218,	16.6	4
107	Reprogramming of the esophageal squamous carcinoma epigenome by SOX2 promotes ADAR1 dependence. *Nature Genetics*, **2021**, 53, 881-894	36.3	6
106	The synergy of BET inhibitors with aurora A kinase inhibitors in MYCN-amplified neuroblastoma is heightened with functional TP53. *Neoplasia*, **2021**, 23, 624-633	6.4	2
105	Targeting serine hydroxymethyltransferases 1 and 2 for T-cell acute lymphoblastic leukemia therapy. *Leukemia*, **2021**,	10.7	1
104	ZMYND8-regulated IRF8 transcription axis is an acute myeloid leukemia dependency. *Molecular Cell* , **2021**, 81, 3604-3622.e10	17.6	8
103	Targeting an Inducible SALL4-Mediated Cancer Vulnerability with Sequential Therapy. *Cancer Research*, **2021**, 81, 6018-6028	10.1	2
102	Dihydropyridine Lactam Analogs Targeting BET Bromodomains.. *ChemMedChem*, **2021**, e202100407	3.7	
101	Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer. *Nature Communications*, **2020**, 11, 2350	17.4	15
100	Using Chemical Epigenetics to Target Cancer. *Molecular Cell*, **2020**, 78, 1086-1095	17.6	18
99	Peptide-Based PROTAC: The Predator of Pathological Proteins. *Cell Chemical Biology*, **2020**, 27, 637-639	8.2	6
98	Selective Targeting of Different Bromodomains by Small Molecules. *Cancer Cell*, **2020**, 37, 764-766	24.3	2

97	Epigenetic CRISPR Screens Identify as a Therapeutic Vulnerability in Non-Small Cell Lung Cancer. *Cancer Research*, **2020**, 80, 3556-3567	10.1	8
96	BET bromodomain proteins regulate transcriptional reprogramming in genetic dilated cardiomyopathy. *JCI Insight*, **2020**, 5,	9.9	12
95	Synthetic Lethal and Resistance Interactions with BET Bromodomain Inhibitors in Triple-Negative Breast Cancer. *Molecular Cell*, **2020**, 78, 1096-1113.e8	17.6	35
94	BET bromodomain inhibition suppresses adipogenesis in mice. *Endocrine*, **2020**, 67, 264-267	4	5
93	Epigenetic CRISPR Screen Identifies as an Immunotherapeutic Target in -Mutant Lung Adenocarcinoma. *Cancer Discovery*, **2020**, 10, 270-287	24.4	68
92	Inhibition of Polo-like kinase 1 (PLK1) facilitates the elimination of HIV-1 viral reservoirs in CD4 T cells ex vivo. *Science Advances*, **2020**, 6, eaba1941	14.3	9
91	High-performance CRISPR-Cas12a genome editing for combinatorial genetic screening. *Nature Communications*, **2020**, 11, 3455	17.4	26
90	BET proteins inhibitor JQ-1 impaired the extinction of remote auditory fear memory: An effect mediated by insulin like growth factor 2. *Neuropharmacology*, **2020**, 177, 108255	5.5	5
89	The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting Therapies. *Cancer Discovery*, **2020**, 10, 1894-1911	24.4	4
88	Diversified Application of Barcoded PLATO (PLATO-BC) Platform for Identification of Protein Interactions. *Genomics, Proteomics and Bioinformatics*, **2019**, 17, 319-331	6.5	4
87	Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma. *Nature Communications*, **2019**, 10, 2400	17.4	18
86	A large-scale drug screen identifies selective inhibitors of class I HDACs as a potential therapeutic option for SHH medulloblastoma. *Neuro-Oncology*, **2019**, 21, 1150-1163	1	11
85	BCL2 Amplicon Loss and Transcriptional Remodeling Drives ABT-199 Resistance in B Cell Lymphoma Models. *Cancer Cell*, **2019**, 35, 752-766.e9	24.3	33
84	Development and preclinical validation of a novel covalent ubiquitin receptor Rpn13 degrader in multiple myeloma. *Leukemia*, **2019**, 33, 2685-2694	10.7	24
83	Dynamic Chromatin Targeting of BRD4 Stimulates Cardiac Fibroblast Activation. *Circulation Research*, **2019**, 125, 662-677	15.7	56
82	Chemical genomics reveals histone deacetylases are required for core regulatory transcription. *Nature Communications*, **2019**, 10, 3004	17.4	55
81	Maintenance and enhancement of human peripheral blood mobilized stem/progenitor cell engraftment after ex vivo culture via an HDACi/SALL4 axis (3465). *Experimental Hematology*, **2019**, 75, 53-63.e11	3.1	2
80	The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting Therapies. *Blood*, **2019**, 134, 877-877	2.2	1

79	Small-molecule BCL6 inhibitor effectively treats mice with nonsclerodermatous chronic graft-versus-host disease. *Blood*, **2019**, 133, 94-99	2.2	14
78	Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma. *Oncogene*, **2018**, 37, 2850-2862	9.2	38
77	YAP1-Mediated Suppression of USP31 Enhances NFB Activity to Promote Sarcomagenesis. *Cancer Research*, **2018**, 78, 2705-2720	10.1	27
76	Functional TRIM24 degrader via conjugation of ineffectual bromodomain and VHL ligands. *Nature Chemical Biology*, **2018**, 14, 405-412	11.7	125
75	BET-inhibition by JQ1 promotes proliferation and self-renewal capacity of hematopoietic stem cells. *Haematologica*, **2018**, 103, 939-948	6.6	14
74	The dTAG system for immediate and target-specific protein degradation. *Nature Chemical Biology*, **2018**, 14, 431-441	11.7	295
73	Structural and Atropisomeric Factors Governing the Selectivity of Pyrimido-benzodiazipinones as Inhibitors of Kinases and Bromodomains. *ACS Chemical Biology*, **2018**, 13, 2438-2448	4.9	31
72	Structure-Guided Design and Development of Potent and Selective Dual Bromodomain 4 (BRD4)/Polo-like Kinase 1 (PLK1) Inhibitors. *Journal of Medicinal Chemistry*, **2018**, 61, 7785-7795	8.3	32
71	CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2. *Journal of Clinical Investigation*, **2018**, 128, 446-462	15.9	72
70	Synergistic effects of BET and MEK inhibitors promote regression of anaplastic thyroid tumors. *Oncotarget*, **2018**, 9, 35408-35421	3.3	8
69	Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma. *ELife*, **2018**, 7,	8.9	70
68	Author response: Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma **2018**,		4
67	R-2HG Exhibits Anti-tumor Activity by Targeting FTO/mA/MYC/CEBPA Signaling. *Cell*, **2018**, 172, 90-105.e23	36.2	479
66	Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms. *Cancer Cell*, **2018**, 33, 29-43.e7	24.3	113
65	Leukemia-specific delivery of mutant NOTCH1 targeted therapy. *Journal of Experimental Medicine*, **2018**, 215, 197-216	16.6	16
64	Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13. *ELife*, **2018**, 7,	8.9	62
63	Resistance to Epigenetic-Targeted Therapy Engenders Tumor Cell Vulnerabilities Associated with Enhancer Remodeling. *Cancer Cell*, **2018**, 34, 922-938.e7	24.3	31
62	YAP1 enhances NF-B-dependent and independent effects on clock-mediated unfolded protein responses and autophagy in sarcoma. *Cell Death and Disease*, **2018**, 9, 1108	9.8	20

61	BET Bromodomain Inhibitors with One-Step Synthesis Discovered from Virtual Screen. *Journal of Medicinal Chemistry*, **2017**, 60, 4805-4817	8.3	31
60	Gene expression profiling of patient-derived pancreatic cancer xenografts predicts sensitivity to the BET bromodomain inhibitor JQ1: implications for individualized medicine efforts. *EMBO Molecular Medicine*, **2017**, 9, 482-497	12	50
59	HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer. *Oncotarget*, **2017**, 8, 80109-80123	3.3	18
58	HIF activation causes synthetic lethality between the tumor suppressor and the histone methyltransferase. *Science Translational Medicine*, **2017**, 9,	17.5	24
57	Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4. *Nature Medicine*, **2017**, 23, 1063-1071	50.5	169
56	Synthetic transcription elongation factors license transcription across repressive chromatin. *Science* , **2017**, 358, 1617-1622	33.3	68
55	Inhibition of BET bromodomain improves anemia in APC mice. *Leukemia and Lymphoma*, **2017**, 58, 989-992	2.9	1
54	Bromodomain and Extraterminal Protein Inhibitor JQ1 Suppresses Thyroid Tumor Growth in a Mouse Model. *Clinical Cancer Research*, **2017**, 23, 430-440	12.9	38
53	Targeting MYC as a Therapeutic Intervention for Anaplastic Thyroid Cancer. *Journal of Clinical Endocrinology and Metabolism*, **2017**, 102, 2268-2280	5.6	29
52	Chronic Myelogenous Leukemia- Initiating Cells Require Polycomb Group Protein EZH2. *Cancer Discovery*, **2016**, 6, 1237-1247	24.4	55
51	Mechanism, Consequences, and Therapeutic Targeting of Abnormal IL15 Signaling in Cutaneous T-cell Lymphoma. *Cancer Discovery*, **2016**, 6, 986-1005	24.4	52
50	Relative Binding Free Energy Calculations Applied to Protein Homology Models. *Journal of Chemical Information and Modeling*, **2016**, 56, 2388-2400	6.1	40
49	Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma. *Proceedings of the National Academy of Sciences of the United States of America*, **2016**, 113, 13162-13167	11.5	89
48	Eradication of Acute Myeloid Leukemia with FLT3 Ligand-Targeted miR-150 Nanoparticles. *Cancer Research*, **2016**, 76, 4470-80	10.1	38
47	Oncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in Lung Cancer. *Cancer Discovery*, **2016**, 6, 1006-21	24.4	71
46	Super enhancers at the miR-146a and miR-155 genes contribute to self-regulation of inflammation. *Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms*, **2016**, 1859, 564-71	6	28
45	An oncogenic MYB feedback loop drives alternate cell fates in adenoid cystic carcinoma. *Nature Genetics*, **2016**, 48, 265-72	36.3	152
44	Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer. *Nature*, **2016**, 529, 413-417	50.4	363

43	An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation. *Nature Medicine*, **2016**, 22, 632-40	50.5	122
42	Inhibition of BET bromodomain attenuates angiotensin II induced abdominal aortic aneurysm in ApoE mice. *International Journal of Cardiology*, **2016**, 223, 428-432	3.2	11
41	BET bromodomain is a novel regulator of TAZ and its activity. *Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms*, **2016**, 1859, 1527-1537	6	12
40	Acetylation site specificities of lysine deacetylase inhibitors in human cells. *Nature Biotechnology*, **2015**, 33, 415-23	44.5	186
39	DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia. *Nature Medicine*, **2015**, 21, 335-43	50.5	160
38	Transcriptional and post-transcriptional control of adipocyte differentiation by Jumonji domain-containing protein 6. *Nucleic Acids Research*, **2015**, 43, 7790-804	20.1	26
37	Inhibitors of emerging epigenetic targets for cancer therapy: a patent review (2010-2014). *Pharmaceutical Patent Analyst*, **2015**, 4, 261-84	0.6	34
36	Synergistic effect of JQ1 and rapamycin for treatment of human osteosarcoma. *International Journal of Cancer*, **2015**, 136, 2055-64	7.5	79
35	Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib. *Blood*, **2015**, 126, 1565-74	2.2	76
34	Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL. *Clinical Cancer Research*, **2015**, 21, 2348-58	12.9	42
33	Structure-guided DOT1L probe optimization by label-free ligand displacement. *ACS Chemical Biology*, **2015**, 10, 667-74	4.9	19
32	Targeted Treatment of FLT3 -Overexpressing Acute Myeloid Leukemia with MiR-150 Nanoparticles Guided By Conjugated FLT3 Ligand Peptides. *Blood*, **2015**, 126, 3784-3784	2.2	1
31	Genome-Wide Mapping Reveals BRD4 in Regulation of Tumor-Driver Genes in Cutaneous T-Cell Lymphoma. *Blood*, **2015**, 126, 589-589	2.2	
30	Genome-wide localization of small molecules. *Nature Biotechnology*, **2014**, 32, 92-6	44.5	138
29	Biased multicomponent reactions to develop novel bromodomain inhibitors. *Journal of Medicinal Chemistry*, **2014**, 57, 9019-27	8.3	67
28	Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells. *Molecular Cancer Therapeutics*, **2014**, 13, 1142-54	6.1	143
27	Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition. *Nature Medicine*, **2014**, 20, 732-40	50.5	213
26	SALL4 Is a Key Factor in HDAC Inhibitor Mediated Ex Vivo Expansion of Human Peripheral Blood Mobilized Stem/Progenitor CD34+CD90+ Cells. *Blood*, **2014**, 124, 1566-1566	2.2	2

25	Targeting BCL6 and Germinal Centers (GCs) in Chronic Graft-Versus-Host Disease (cGVHD) Using Direct and Epigenomic Therapies. *Blood*, **2014**, 124, 535-535	2.2	2
24	Eradication of Chronic Myelogenous Leukemia By Inactivation of the Polycomb Group Protein EZH2. *Blood*, **2014**, 124, 778-778	2.2	1
23	Selectively Targeting Mutated NOTCH1 with a Folate-Thapsigargin Derivative. *Blood*, **2014**, 124, 2158-2158	2.2	
22	Structure-Guided Design of DOT1L Methyltransferase Inhibitors By a Novel, Label Free Assay Platform. *Blood*, **2014**, 124, 4811-4811	2.2	
21	Superior Pre-Clinical Activity of BET (Bromodomain and Extra terminal) Protein Antagonist Combined with Ibrutinib, Panobinostat or Carfilzomib Against Human Mantle Cell Lymphoma (MCL) Cells. *Blood*, **2014**, 124, 918-918	2.2	
20	Mechanistic Role of HEXIM1 Induction in BRD4-Antagonist Mediated Growth Inhibition, Differentiation and in Vivo Lethal Activity Against Human AML Blast Progenitor Cells. *Blood*, **2014**, 124, 3534-3534	2.2	
19	BET acetyl-lysine binding proteins control pathological cardiac hypertrophy. *Journal of Molecular and Cellular Cardiology*, **2013**, 63, 175-9	5.8	118
18	Selective HDAC1/HDAC2 inhibitors induce neuroblastoma differentiation. *Chemistry and Biology*, **2013**, 20, 713-25		68
17	Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma. *Cancer Cell*, **2013**, 24, 777-90	24.3	491
16	BET bromodomains mediate transcriptional pause release in heart failure. *Cell*, **2013**, 154, 569-82	56.2	277
15	Bromodomain and extraterminal (BET) protein inhibition suppresses human T cell leukemia virus 1 (HTLV-1) Tax protein-mediated tumorigenesis by inhibiting nuclear factor B (NF-B) signaling. *Journal of Biological Chemistry*, **2013**, 288, 36094-105	5.4	30
14	Targeting MYCN in neuroblastoma by BET bromodomain inhibition. *Cancer Discovery*, **2013**, 3, 308-23	24.4	460
13	Disruption Of Super Enhancer-Driven Cancer Dependencies In Diffuse Large B-Cell Lymphoma. *Blood*, **2013**, 122, 3021-3021	2.2	1
12	Combined Therapy With BRD4 Antagonist and JAK Inhibitor Is Synergistically Lethal Against Human Myeloproliferative Neoplasm (MPN) Cells. *Blood*, **2013**, 122, 2842-2842	2.2	1
11	BRD4 Antagonist and Histone Deacetylase Inhibitor: A Novel Synergistic Combination Against Human Acute Myeloid Leukemia (AML) Cells. *Blood*, **2013**, 122, 485-485	2.2	1
10	Combined Therapy With BRD4 Antagonist and FLT3 Inhibitor Exerts Synergistic Activity Against Cultured and Primary AML Blast Progenitors Expressing FLT-ITD. *Blood*, **2013**, 122, 3821-3821	2.2	
9	Genome-Wide RNAi Screen Identifies The Mechanistic Role For DOT1L In MLL-Rearranged Leukemia. *Blood*, **2013**, 122, 598-598	2.2	1
8	BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. *Blood*, **2012**, 120, 2843-52	2.2	298

7	Small-molecule inhibition of BRDT for male contraception. *Cell*, **2012**, 150, 673-84	56.2	277
6	Targeting STAT5 in Leukemia Through Inhibition of Bromodomain Proteins. *Blood*, **2012**, 120, 399-399	2.2	1
5	BET Bromodomain Inhibition Targets Both c-Myc and IL7R in Acute Lymphoblastic Leukemia. *Blood*, **2012**, 120, 672-672	2.2	
4	RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. *Nature*, **2011**, 478, 524-8	50.4	1398
3	BET bromodomain inhibition as a therapeutic strategy to target c-Myc. *Cell*, **2011**, 146, 904-17	56.2	2045
2	Inhibition of c-Myc Expression and Function in Hematologic Malignancies. *Blood*, **2011**, 118, 1409-1409	2.2	
1	Selective inhibition of BET bromodomains. *Nature*, **2010**, 468, 1067-73	50.4	2725